A Ercan

A Pierce

AM Dias

B Buszewski

C Huang

DJ Harvey

E Bause

E Theodoratou

E Vartiainen

EH Schreuders

ES Collins

F Dall’Olio

GS Karagiannis

H JA

H Stockmann

H Stöckmann

I Gudelj

I Trbojević Akmačić

J Aitchison

J Bones

J Hamfjord

J Lu

JD Marth

JN Arnold

JW Dennis

K Mariño

K Murata

L Royle

LR Ruhaak

M Novokmet

M Pezer

MP Campbell

MV Croce

O Gornik

R Saldova

SG Baker

SS Pinho

T Roitsch

UM Abd Hamid

W M.

WR Alley

X Robin

Y Freund

Scientific Reports

AbstractAberrant glycosylation has been associated with a number of diseases including cancer. Our aim was to elucidate changes in whole plasma N-glycosylation between colorectal cancer (CRC) cases and controls in one of the largest cohorts of its kind. A set of 633 CRC patients and 478 age and gender matched controls was analysed. Additionally, patients were stratified into four CRC stages. Moreover, N-glycan analysis was carried out in plasma of 40 patients collected prior to the initial diagnosis of CRC. Statistically significant differences were observed in the plasma N-glycome at all stages of CRC, this included a highly significant decrease in relation to the core fucosylated bi-antennary glycans F(6)A2G2 and F(6)A2G2S(6)1 (P &lt; 0.0009). Stage 1 showed a unique biomarker signature compared to stages 2, 3 and 4. There were indications that at risk groups could be identified from the glycome (retrospective AUC = 0.77 and prospective AUC = 0.65). N-glycome biomarkers related to the pathogenic progress of the disease would be a considerable asset in a clinical setting and it could enable novel therapeutics to be developed to target the disease in patients at risk of progression.</jats:p

Margaret Doherty

Evropi Theodoratou

Ian Walsh

Barbara Adamczyk

Henning Stöckmann

Felix Agakov

Maria Timofeeva

Irena Trbojević-Akmačić

Frano Vučković

Fergal Duffy

Ciara A. McManus

Susan M. Farrington

Malcolm G. Dunlop

Markus Perola

Gordan Lauc

Harry Campbell

Pauline M. Rudd

Crossref

Plasma N-glycans in colorectal cancer risk

Doherty, Margaret

Theodoratou, Evropi

Walsh, Ian

Adamczyk, Barbara

Stoeckmann, Henning

Agakov, Felix

Timofeeva, Maria

Trbojevic-Akmacic, Irena

Vuckovic, Frano

Duffy, Fergal

McManus, Ciara A.

Farrington, Susan M.

Dunlop, Malcolm G.

Perola, Markus

Lauc, Gordan

Campbell, Harry

Rudd, Pauline M.

Julkari

Aberrant glycosylation has been associated with a number of diseases including cancer. Our aim was to elucidate changes in whole plasma N-glycosylation between colorectal cancer (CRC) cases and controls in one of the largest cohorts of its kind. A set of 633 CRC patients and 478 age and gender matched controls was analysed. Additionally, patients were stratified into four CRC stages. Moreover, N-glycan analysis was carried out in plasma of 40 patients collected prior to the initial diagnosis of CRC. Statistically significant differences were observed in the plasma N-glycome at all stages of CRC, this included a highly significant decrease in relation to the core fucosylated bi-antennary glycans F(6)A2G2 and F(6)A2G2S(6)1 (P &lt; 0.0009). Stage 1 showed a unique biomarker signature compared to stages 2, 3 and 4. There were indications that at risk groups could be identified from the glycome (retrospective AUC = 0.77 and prospective AUC = 0.65). N-glycome biomarkers related to the pathogenic progress of the disease would be a considerable asset in a clinical setting and it could enable novel therapeutics to be developed to target the disease in patients at risk of progression.</p

Stöckmann, Henning

Trbojević-Akmačić, Irena

Vučković, Frano

McManus, Ciara A

Farrington, Susan M

Dunlop, Malcolm G

Rudd, Pauline M

Edinburgh Research Explorer

https://www.pure.ed.ac.uk/ws/files/61439939/Plasma_N_glycans_in_colorectal_cancer_risk.pdf

Plasma N-glycans in colorectal cancer risk

Abstract

Similar works

Full text

Available Versions

Crossref

Julkari

Edinburgh Research Explorer